Publication | Closed Access

Safety, pharmacokinetics, and antiviral activity of the cyclophilin inhibitor NIM811 alone or in combination with pegylated interferon in HCV-infected patients receiving 14 days of therapy

Pegylated InterferonViral HepatitisNeurovirologyAntiviral ActivityAntiviral Drug DevelopmentAntiviral TherapyHepatitisAntiviral ResponsePharmacotherapyCyclophilin Inhibitor Nim811Antiviral DrugMedicine